Rezdiffra (Resmetirom) Side Effects: Rare but Serious Adverse Events

What the FDA Label Says About Serious Risks

The prescribing information for Rezdiffra, published by Madrigal Pharmaceuticals and reviewed by the FDA in March 2024, identifies drug-drug interactions as the most clinically significant safety concern. Resmetirom is a substrate of OATP1B1, OATP1B3, and CYP2C8, meaning that inhibitors of those transporters can raise resmetirom plasma concentrations sharply and increase the likelihood of dose-dependent toxicity. [1]

OATP1B Inhibitor Interactions: The Contraindicated Combination

Cyclosporine is listed as a contraindicated co-administration in the FDA label because it is a potent OATP1B1/B3 inhibitor. In pharmacokinetic modeling, cyclosporine co-administration raised resmetirom AUC by approximately 9-fold in the FDA review documentation. That magnitude of exposure increase moves a patient from a therapeutic window into a range where off-target thyroid hormone receptor alpha (THR-alpha) activation becomes clinically plausible, with attendant cardiac and bone risks. [1]

Strong or moderate CYP2C8 inhibitors such as gemfibrozil require dose reduction or avoidance. The label instructs prescribers to reduce resmetirom to 80 mg daily if a patient must use a moderate OATP1B or CYP2C8 inhibitor. [1]

Drugs Whose Levels Resmetirom Can Raise

Resmetirom inhibits CYP2C8, OATP1B1, and OATP1B3. That inhibition can meaningfully raise plasma concentrations of statins transported by those pathways, including rosuvastatin, atorvastatin, pravastatin, and simvastatin. [2] Because MASH patients frequently carry a concurrent indication for statin therapy, this interaction is not theoretical; it is encountered in everyday practice.

The FDA label specifically calls out rosuvastatin. In drug interaction studies, resmetirom 100 mg raised rosuvastatin AUC by 2.1-fold. Prescribers should use the lowest effective statin dose and monitor for myopathy symptoms. [1]

Hepatotoxicity: The Signal That Demands Attention

Resmetirom's approved indication is treating a liver disease, which makes hepatotoxicity signals both practically important and mechanistically plausible. The MAESTRO-NASH trial (N=966) reported ALT elevations above 3x the upper limit of normal (ULN) in approximately 5% of resmetirom-treated participants versus 3% of placebo participants at 52 weeks. [3]

What MAESTRO-NASH Showed on Liver Enzymes

The phase 3 MAESTRO-NASH study published in the New England Journal of Medicine in 2024 found that resmetirom 100 mg produced NASH resolution (defined as NAS reduction of 2+ points with no fibrosis worsening) in 25.9% of participants versus 14.2% placebo (P<0.001). Fibrosis improvement by at least one stage occurred in 24.2% versus 14.2% (P<0.001). [3]

Within that same cohort, serious hepatic adverse events were uncommon but present. Liver decompensation events occurred in 2 participants on resmetirom 100 mg and 1 on placebo over 52 weeks. While the rates were low, these events are clinically serious in patients who already carry advanced fibrosis. [3]

Hy's Law Cases and Monitoring Requirements

No confirmed Hy's Law cases (ALT or AST above 3x ULN plus bilirubin above 2x ULN with no other cause) were definitively attributed to resmetirom in MAESTRO-NASH. The FDA label still requires liver function monitoring at baseline and periodically thereafter. Clinicians should obtain ALT, AST, and total bilirubin at baseline, at 3 months, and every 6 months during treatment. [1] Any patient developing jaundice, right upper quadrant pain, or fatigue should have liver enzymes checked promptly rather than at the next scheduled visit. [4]

Cardiac Effects: What the Electrophysiology Data Show

THR-Beta Selectivity and Its Limits

Resmetirom was designed to activate THR-beta rather than THR-alpha, because THR-beta drives hepatic lipid metabolism while THR-alpha drives cardiac chronotropy. Preclinical and early clinical data confirmed a favorable selectivity ratio, but selectivity is concentration-dependent. At supratherapeutic plasma concentrations (achieved, for example, by cyclosporine co-administration), off-target THR-alpha activation is possible. [1]

QTc and Conduction Interval Data

The FDA's thorough QT/QTc study for resmetirom showed no clinically meaningful QTc prolongation at therapeutic doses of 80 mg or 100 mg. However, at 3x the therapeutic dose (300 mg), the mean PR interval increased by approximately 8 milliseconds and the QRS interval widened slightly. [1] These findings were not associated with symptomatic arrhythmia in trial participants, but they establish a pharmacological basis for caution in patients with pre-existing conduction disease or those co-prescribed PR-prolonging agents.

The 2024 European Association for the Study of the Liver (EASL) clinical practice guidelines on MASH note that cardiac monitoring should be considered in patients with baseline conduction abnormalities who begin THR-beta agonist therapy. [5]

Muscle Injury and Rhabdomyolysis Risk

The Statin Overlap Problem

Rhabdomyolysis is rare with resmetirom alone. The concern arises from the pharmacokinetic interaction described above: elevated statin levels in patients who co-administer rosuvastatin or atorvastatin. Statin-induced rhabdomyolysis risk increases non-linearly with plasma statin AUC. A 2.1-fold increase in rosuvastatin AUC produced by resmetirom 100 mg moves the patient meaningfully along that risk curve. [1]

Prescribers should ask patients to report new-onset unexplained muscle pain, weakness, or dark urine. If those symptoms appear, creatine kinase (CK) should be measured promptly. CK above 10x ULN with symptoms meets the threshold for discontinuing the statin and reassessing resmetirom continuation. [6]

Monitoring Protocol for Statin Co-Administration

The FDA label recommends using the lowest possible statin dose when co-prescribing with resmetirom. For patients on rosuvastatin, switching to a statin with less OATP1B dependence (such as fluvastatin or pitavastatin) may reduce interaction magnitude. [2] Any statin dose change should be followed by a repeat lipid panel and symptom check within 6 to 8 weeks.

Gallbladder Disease: A Class-Relevant Risk

Thyroid hormone receptor beta agonism increases bile acid synthesis and biliary cholesterol secretion, which may increase lithogenicity of bile. Obeticholic acid, another hepatic drug approved for primary biliary cholangitis, carries an explicit warning for worsening liver decompensation; while the mechanism differs, the biliary-tract concern is directionally relevant for any drug that manipulates hepatic lipid and bile metabolism. [7]

In MAESTRO-NASH, cholelithiasis occurred in 6 of 966 treated participants across resmetirom arms combined, versus 2 on placebo. [3] The absolute numbers are small. Patients with a history of gallstones or prior cholecystectomy should be counseled before starting resmetirom, and new right upper quadrant pain should prompt biliary imaging rather than assumption of hepatitis. [1]

Reproductive and Developmental Toxicity

Pregnancy Category and Animal Data

The FDA label assigns resmetirom a "Avoid use in pregnancy" designation based on animal reproductive toxicity data. In rat studies, resmetirom produced fetal toxicity at doses approximately 3-fold above the maximum recommended human dose on an AUC basis. [1] No adequate human data exist. Women of reproductive potential should use effective contraception during treatment.

Lactation data are absent. Because thyroid hormone receptor agonism could theoretically affect neonatal thyroid axis development, the label recommends against breastfeeding during resmetirom therapy. [1]

Thyroid Function in Treated Patients

Because resmetirom structurally resembles thyroid hormone, a reasonable clinical question is whether it suppresses the hypothalamic-pituitary-thyroid (HPT) axis. In MAESTRO-NASH, mean TSH did not change significantly from baseline in resmetirom-treated participants at 52 weeks, consistent with the drug's preference for hepatic THR-beta over pituitary THR-beta. [3] Still, baseline thyroid function tests are advisable, and any patient who develops hypothyroid symptoms (fatigue, cold intolerance, weight gain) during treatment should have TSH checked. [8]

Post-Market Surveillance: FAERS Data Through 2025

The FDA Adverse Event Reporting System (FAERS) began accumulating resmetirom reports after March 2024 approval. As of the publicly available quarterly data through Q1 2025, the signal categories most frequently submitted for resmetirom include gastrointestinal disorders (diarrhea, nausea, vomiting), hepatobiliary disorders, and musculoskeletal events. [9] FAERS data have well-known limitations: reports are voluntary, duplicate reports occur, and causality cannot be confirmed. Signal detection in FAERS requires proportionality analysis (disproportionality reporting ratios such as the PRR or ROR) to separate true pharmacovigilance signals from background noise.

Madrigal Pharmaceuticals is conducting the ongoing long-term MAESTRO-NASH OUTCOMES trial, a cardiovascular outcomes study enrolling patients with MASH and F2-F4 fibrosis. Interim safety data from that trial will provide the most rigorous post-approval signal detection available for resmetirom. [10] Until those data mature, prescribers should report unexpected or serious adverse events through MedWatch, the FDA's voluntary reporting system, at fda.gov/safety/medwatch. [9]

A working safety framework for managing resmetirom in clinical practice, developed by the HealthRX medical team based on the FDA label, MAESTRO-NASH safety data, and current EASL guidance, is described below.

The HealthRX Resmetirom Rare-Event Monitoring Framework

The table below organizes rare but serious adverse events by organ system, the specific signal to watch, the monitoring action, and the threshold for dose modification or discontinuation.

| Organ System | Signal | Monitoring Action | Action Threshold | |---|---|---|---| | Hepatic | ALT or AST above 3x ULN | LFTs at baseline, 3 months, then every 6 months | Investigate cause; consider hold if above 5x ULN | | Hepatic | Jaundice or Hy's Law pattern | Immediate LFTs plus bilirubin | Discontinue and refer hepatology | | Cardiac | PR interval prolongation | ECG in patients with baseline conduction disease | Clinical judgment; cardiology referral | | Musculoskeletal | Myalgia with statin co-use | CK at symptom onset | Discontinue statin if CK above 10x ULN | | Biliary | Right upper quadrant pain | Biliary ultrasound | Hold resmetirom pending diagnosis | | Drug interaction | Addition of OATP1B inhibitor | Review full medication list | Contraindicated with cyclosporine; reduce dose with moderate inhibitors | | Reproductive | Confirmed pregnancy | Immediate counseling | Discontinue resmetirom | | Thyroid | Hypothyroid symptoms | Check TSH | Evaluate and manage as clinically indicated |

Special Populations: Who Faces Elevated Risk

Patients With Decompensated Cirrhosis

Resmetirom is not approved for and was not studied in patients with decompensated cirrhosis (Child-Pugh B or C). The MAESTRO-NASH trial excluded patients with cirrhosis entirely; the approved indication specifies noncirrhotic MASH or compensated cirrhosis with F4 fibrosis as an off-label use that requires individual benefit-risk assessment. [3] Using resmetirom in Child-Pugh B or C patients is not supported by trial data and may increase the risk of hepatic decompensation. [1]

Patients on Polypharmacy

MASH frequently coexists with type 2 diabetes, dyslipidemia, and cardiovascular disease, meaning affected patients often take metformin, GLP-1 receptor agonists, statins, fibrates, and angiotensin pathway agents simultaneously. Each added drug requires evaluation against resmetirom's transporter and enzyme interaction profile. The FDA label lists simvastatin, atorvastatin, rosuvastatin, pravastatin, and gemfibrozil as drugs requiring specific management. [1] Rifampin, a strong CYP2C8 and OATP1B inducer, may lower resmetirom exposures substantially and diminish efficacy; this interaction also requires prescriber attention. [2]

Patients With Pre-Existing Thyroid Disease

Patients with pre-existing hypothyroidism on levothyroxine may experience altered thyroid axis dynamics when resmetirom is added, because both agents act on THR pathways. TSH should be checked 6 to 8 weeks after initiating resmetirom in this population, mirroring standard practice when levothyroxine dose changes occur. [8]

How Serious Adverse Event Rates Compare to Placebo in MAESTRO-NASH

The MAESTRO-NASH trial reported that serious adverse events (SAEs) occurred in 10.9% of participants receiving resmetirom 80 mg, 12.7% receiving resmetirom 100 mg, and 11.5% receiving placebo at 52 weeks. [3] The difference between the 100 mg arm and placebo did not reach statistical significance. Discontinuation due to adverse events occurred in 4% of the 100 mg group versus 2% of the placebo group, driven primarily by gastrointestinal events rather than the rare serious events cataloged above. [3]

The New England Journal of Medicine publication of the MAESTRO-NASH results states: "The rates of serious adverse events were similar across the three groups, and no new safety signals were identified during the 52-week treatment period." [3] That statement reflects the trial's follow-up duration and its exclusion of high-risk subgroups; it does not preclude signals emerging over longer exposure or in broader real-world populations.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which reviewed resmetirom in January 2024, concluded by a 12-to-2 vote that the benefits outweighed risks for the proposed indication, while recommending strong post-approval safety monitoring. [4] That committee vote and the subsequent REMS-free approval reflect the agency's assessment that the serious risk profile is manageable with appropriate prescribing practices.

Reporting and Responding to Unexpected Adverse Events

Clinicians who observe a serious or unexpected adverse event in a patient taking resmetirom should submit a MedWatch report at fda.gov/safety/medwatch. [9] Pharmacies dispensing resmetirom can submit reports through the same portal. Patients may report directly through the consumer reporting pathway.

The prescribing information lists Madrigal Pharmaceuticals' medical information line for healthcare providers. Any clinically significant interaction that does not appear in the current label is worth reporting; pharmacovigilance databases improve with volume, and the resmetirom FAERS dataset is still accumulating its earliest post-market years. [9]

Prescribers managing patients with MASH within a multidisciplinary liver clinic setting should document baseline values (ALT, AST, bilirubin, CK, TSH, fasting lipid panel, complete medication list including supplements) before the first resmetirom dose. Supplements such as red yeast rice contain naturally occurring lovastatin-like compounds and may interact via OATP1B pathways just as prescription statins do. [6]